I-FABP is decreased in COVID-19 patients, independently of the prognosis.

Kevin GuedjMathieu UzzanDamien SoudanCatherine TrichetAntonino NicolettiEmmanuel WeissHana ManceauAlexandre NuzzoOlivier CorcosXavier TretonKatell Peoc'h

Published in: PloS one (2021)

In this pilot study, we observed a low I-FABP concentration in COVID-19 patients either with or without gastrointestinal symptoms, of which the pathophysiological mechanisms and clinical impact remain to be established. Further explorations on a larger cohort of patients will be needed to unravel the molecular mechanism of such observation, including the effects of malabsorption and/or abnormal lipid metabolism.

Keyphrases

end stage renal disease
sars cov
newly diagnosed
ejection fraction
binding protein
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes
patient reported